ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1551

The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

Saja Almaaitah1, Chao Zhang2 and alexandra villa forte1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2022

Keywords: Computed tomography (CT), Imaging, Magnetic resonance imaging (MRI), Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a major challenge. In addition to clinical assessment, laboratory and imaging tests are routinely used in the follow up of patients with TA. Serial MRA and CTA have been performed at various intervals, most commonly every 6 to 12 months. However, the best imaging interval is unknown and currently decided on an individual basis. Risk of CTA radiation and the cumulative MRA gadolinium contrast in the brain can be major concerns over many years of disease. The aim of this study is to evaluate correlation between imaging findings, clinical outcome, and change in therapy in TA.

Methods: Retrospective chart review of all patients with TA seen at the Vasculitis Clinic at the Cleveland Clinic between 2002 and December 2020, and who had at least 3 follow up office visits with either CTA or MRA imaging obtained on each visit. Data collection included demographics, disease manifestations, laboratory and imaging results, treatment and disease complications. Bayesian generalized mixed effect model was performed to assess the relationship between clinical variables and outcome.

Results: 94 patients met the inclusion criteria. Median age at diagnosis was 35 years. 89.4% were females. Median follow up duration was 7.6 years (IQR, 4.6; 11.5) and median interval follow up between visits was 8.3 months (IQR, 5.5; 13.8). Patients had a total number of 785 follow up visits, during which 681 MRA and 104 CTA images were obtained. Active imaging was defined as: new stenosis, occlusion, aneurysms or dissection or progressive prior lesions. Stable imaging was defined as: no new or progressive lesions or improvement in the prior abnormal lesions. Out of 785 imaging performed, 133 (17%) were defined as active and 652 (83%) were stable. Out of 133 visits with active imaging, TA was active on 53% and was stable on 47% as deemed by the treating physician. Out of 652 visits with stable imaging, TA was active on 14% and stable on 86%. Therapy was increased in 19.4% of all visits. 50% of patients who presented with new or worsening symptoms were deemed to have active disease, versus patients who presented with abnormal labs (13%) or active imaging (38.9%).

Conclusion: In our TA population, a minority of the routine images showed new or progressive lesions. Less than half of these were associated with active disease in the absence of new/worsening symptoms and abnormal labs. Therapy was increased in a small number of follow up visits, and was as likely to occur based on clinical symptoms as compared to imaging results.

Supporting image 1

Table 1: Summary table for total visits. Continuous variables are summarized using medians [IQR], categorical variables are summarized using counts (%). *Included: Abatacept, adalimumab, azathioprine, cyclophosphamide, etanercept, glucocorticoids, infliximab, methotrexate, mycophenolate mofetil, rituximab, tocilizumab. +Included: Angioplasty with/without stenting, bypass surgery, aortic aneurysmal repair

Supporting image 2

Table 2: Comparison between imaging results vs other clinical parameters in determining clinical outcome. *with normal labs and no new/worsening symptoms; †stable imaging and no new/worsening symptoms; §stable imaging and normal labs

Supporting image 3

Figure 1: Vessel Involvement at first visit (blue) vs the duration of the study (orange)


Disclosures: S. Almaaitah, None; C. Zhang, None; a. villa forte, None.

To cite this abstract in AMA style:

Almaaitah S, Zhang C, villa forte a. The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-utility-of-imaging-studies-mra-and-cta-in-long-term-monitoring-for-patients-with-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-utility-of-imaging-studies-mra-and-cta-in-long-term-monitoring-for-patients-with-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology